As reviewed elsewhere23, 45, peptide epitopes targeting CD4+ T cells have distinct advantages over intact antigens, and yet the mechanism by which peptide therapy prevents and treats ongoing autoimmune and allergic diseases is poorly defined. The gene discussed is CD4; the disease is allergic disease.